



Grape King Bio (1707 TT) Investor Presentation

Jan 2022



Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.





Company Background



Investment Highlights



We are industry leade

- ✓ We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2019.
- ✓ We operate the second largest direct-selling company Pro-Partner in Taiwan (2019 market share: 8.3%).




Strong R&D capabilities

- ✓ We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- Our expertise in raw materials allow us to develop health supplements serving different benefits.
 Therefore, many of our products are TFDA approved for different health benefits.
- We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ✓ We have delivered a solid earnings during 2008-2020 (CAGR of 19%/average ROE 25%).
- ✓ We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.



Company Overview: Three core business units



1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM

> Locus of all key ingredient design, formulation, and production for the whole Group.

2. Pro-Partner (60%-own) **Taiwan direct selling distribution**


A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.




3. Grape King Shanghai (100%-own) China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.

2021 REVENUE



9M21 NET PROFIT



■ Grape King Taiwan ■ Pro-Partner ■ Grape King Shanghai

Complete Product Range






Competitive Strengths - Strong Products Capabilities

We acquired more than 186 patents and published over 84 research papers.

Also, we acquired more than 10 TFDA Health Food certifications on our products.





2017~2020 : 8 countries, 125 awards



Competitive Strengths - State-of-the-Art Production Facilities






1. Grape King Taiwan





Taiwan - Grape King Brand Sales Channels



Our best seller Slim Turmeric Complex

22% of 1H20 revenue

挑戰美人力 雙 向 輔 助

*95%高含量薑黃

X 獨家GKC6益生菌

葡萄王生技獨家研發益生菌複方薑黃 成份創新再升級。



Our 2nd seller **ComeBest Series** 17% of 1H revenue

Energy drinks that restore energy and provides necessary vitamins



Our third best seller –
Probiotics King
14% of 1H21 revenue





2. Pro-Partner





Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest local direct selling company in Taiwan based on revenue.
 - One of the fastest growing direct selling companies in Taiwan (15% sales CAGR from 2008 to 2020)
- Second largest overall direct selling company in Taiwan. (2019 market share: 8.3%)
- 35 Smallest product range 35 Health and Beauty products among the top 5
- No. 41 in the worldwide direct selling company rankings for 2021

(Source: 2021 DSN Global 100- based on 2020 revenues)






Bai Yi Jie (toothpaste)



- Grape King's Lactobacillus pentosus GK4
 - → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol
 - → Anti-plaque
- Sodium fluoride
 - → Prevent enamel erosion
- Mint
 - → Sooth teeth

Hi Spray (oral spray)



→ Inhibit 13 kinds of oral bacteria & Prevent cavities

- Sorbitol
 - → Anti-plaque
- Thyme
 - → Freshen breath
- Mint
 - → Sooth teeth








How is Pro-Partner different from other direct selling companies?

85% of Pro-Partner's sales are contributed by old members





Our member retention rate is remarkably high number among peers

Members retention rate



Executive distributor growth inline with membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group. However, due to Covid-19, our membership growth paused in 2020 as most of the training activities were restricted, nonetheless, our executive distributors continue to grow along with their contribution.

Pro-Partner membership growth rate





How is Pro-Partner different from other direct selling companies?

Products purchase

- ✓ No minimum purchase requirement.
- ✓ No inventory pressure. (Members buy products directly from the company)

Products' uniqueness



- Higher entry barrier for Products (bioresearched and engineered).
- ✓ Symbol of national certifications.
- Products are mostly manufactured inhouse rather than outsourced.

Support



Managed by Grape King, a well-respected health food company in Taiwan, so we can offer dedicated customer service and support.

Training



- ✓ All the trainings and venues are held by the company, so we can have consistent training quality.
- ✓ All the trainings are free to members.

Compensation



- Transparent compensation structure.
- ✓ All purchases can be accumulated.
- All compensation are paid to sales contribution and directly to the members by the company.



3. Grape King Shanghai






Grape King Shanghai Overview

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.





^{*}In 2019, the overall demand was impacted by China government' s tightening on direct-selling and healthcare industry & in 2020 the China consumption recovery has been softer-than-expected under the pandemic.





Our Goals and Strategies





Our business tied to 5 megatrends; amplified by Covid



Urbanization and Globalization

Hygiene is a basic need and also the foundation of health of all mankind and societies



Increased
Awareness of
Self-care

Rising conscious of a healthier lifestyle and personal well-being



Growing Ageing Society

Low birth rate and a growing ageing population



Digitalization

Digital is reshaping consumer behavior and shopping habits



Sustainability

Sustainability is a growing business priority, and even more so after Covid

We have identified our R&D focus fitting in the megatrends



Medicinal Mushrooms

Personal Hygiene


Respiratory Health/Anti-Bacterial

Lower risks factor (Antrodia)

Memory Improvement (Lionsmane)







Mood Improvement

Weight Management

Eye Health (Cordyceps Sobolifera)

Sleeping Quality (Armillaria mellea)











Consumers' Experience is the Core of Everything We Do

Our Mission

"Cultivate and manufacture the best health-food supplements that are affordable to everyone.

Think Healthy, Think Grape King"

How?

- Offer scientifically-proven specialty products with competitive pricing
- Create lifestyle branding and storytelling based on personal experiences
- Leverage websites, e-commerce and digital marketing to drive customer excitement and loyalty
- Deliver customized experiences to encourage trial and repeat purchases





Powerful Brand Building

Capturing the distributors and consumers "mindshare" as the "go-to" brand for Liver Protection



Grape King Antrodia King (liver protection)

Stress causes high blood pressure but also harms liver

As well as the "go-to" brand for Probiotics



Leading to strong growth from our virtual channels



Grape King Taiwan's revenue from virtual channels grew by 21% in 1-3Q21 and accounted ~50%* of total revenue.

*Not including ODM revenue



Our Growth Strategies for Three Key Businesses



Key Objectives

Grape King Taiwan

- Market share gain
- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

iaw matemate b

Pro-Partner

- · Unlock growth ceiling
- Improving demand forecast, sales visibility, and products time to market

✓ Market share gain through products upgrade and deeper channels penetration

Levers

- Business expansion through penetrating new product categories
- Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- Focus on growing younger members.
- ✓ Duplicate Taiwan success in new geographies

Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- Develop non-direct/WeChat customers
- Capture more business opportunities through local strategic partnerships and alliances

Growing on Giant's Shoulder



Channels & Distribution Collaboration

 Physical Channels: Taiwan~6,000 stores/ China~ 400 stores / Southeast Asia ~ 3,000 stores (including convenience stores, pharmacies, department stores)

Virtual Channels











 Taiwan/overseas mutual OEM production

R&D Collaboration

- New adjacencies (such as F&B) expansion
- R&D collaboration, joint product development
- Products agency
- Food safety enhancement

Our Joint Products with UPEC have recently been launched





2020



PURPOSE-LED BRAND

72%

of our revenues are aligned with United Nation's (UN) Sustainable Development Goals (SDGs)



Adopted SASB indicators for ESG communications with investors



CLEANER PLANET

318 kg

of CO2e of carbon emission reduced in 2020



Of renewable energy usage by 2035 (15% by 2030)



FAIRER SOCIETY

815 hrs

service hours were invested in community investment projects in 2020

NT\$1.6 mn

invested in employee health management and health promotion



STRONGER STEWARDSHIP

33%

Of Board independence is expected in the coming Board election

42%

of female board members expected in the coming Board election, higher than TWSE average of 13.4%

Third-Party ESG Credentials



Top 5% among all TWSE companies in 2020 Corporate Governance Assessment



ESG Risk Rating of 20.8, **ranked no. 5** in Global Personal Product companies



Top 35% of all global companies, and the top scoring supplier of our ODM client

6

Production

Capsules

PKI

PIC/S

Fine Granule

Liquids-Biq CC

Liquids-Small CC 1 M bottles

Our Capacity and Expansion Plan

Grape King Specialist Fermentation & Manufacturing Site*

Monthly Capacity

2020

7 M capsules

2 M pack

4.2 M bottles

1 M bottles

1.4 M bottles

0.8 M packs





Production	Monthly Capacity					
Line	2019	2020				
Liquids(Glass)	18 M bottles	18 M bottles				
Liquids (Retort Pouch)	3 M packs	3 M packs				
Powder	15 M pack	15 M pack				
Capsules	7 M capsules	7 M capsules				
Troches	63 M capsules	63 M capsules				

Grape King Bio-Tech Headquarter



Production	IVICITOR	Capacity	CALLE
Line	2019	2020	Start
Capsules	13M capsules	13M capsules	-
Fine Granule	15M pack	15M pack	-
Powder	1.8M packs	1.8M packs	-
Jelly foil	-	7.2M packs**	3Q20


Monthly Canacity

Grape King Bio-Tech Research Institute



Production	Capacity				
Line	2019	2020			
Lactobacilli	40 tons	40 tons			
Mushroom	60 tons	60 tons			

**Monthly capacity =30,000 packs/hr x 12 hrs/day x 20 working days/month



2019

7 M capsules

2 M pack

4.2 M bottles

1.4 M bottles

0.8 M packs



















^{*}Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in revenue for Grape Kina.





Financial Performance


"

Financial Highlights


Historical revenue vs. operating profit



Historical EPS vs. ROCE




Historical gross margin vs. operating margin



Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.


Historical cash dividend payout





Revenue Breakdown (2021 vs. 2020)





1.Grape King Taiwan NT\$ 914mn (+36.7% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues.

2.Pro-Partner NT\$ 8bn (+3.6% YoY)


Pro-Partner's 3Q21 growth was offset by a lower 1Q21 due to extraordinary high base in 1Q20.

3. Grape King Shanghai NT\$ 884mn (+13.2% YoY)

China demand recovery has been softerthan-expected in 2021 if excluding the low base in 1Q20.



Revenue Breakdown (4Q21 vs. 4Q20)



1. Grape King Taiwan NT\$ 231mn (+25.5% YoY)

Thanks to strong sales of our own brand products as well as higher ODM revenues. However, higher opex was incurred due to launch of our new beverage products (Kombucha and Probiotic Water).

2.Pro-Partner NT\$ 2,455mn (+5% YoY)

Despite worsening pandemic in Taiwan, Pro-Partner was able to transition its members trainings and sales activities from offline to online.


3. Grape King Shanghai NT\$ 231mn (+5% YoY)

China consumption recovery remained slowerthan-expected as Delta-variant breaches China again in 3Q21.

4Q20 REVENUE



4Q20 NET PROFIT





Five-Year Income Statement

(NT\$ m)	2016	2017	2018	2019	2020 9M21	YoY (%)						
(NI \$ III)	2010	2017	2016	2017	2020	7/1/21	2016	2017	2018	2019	2020	9M21
Revenue	9,185	9,388	9,183	9,239	9,168	6,880	26.7	2.2	(2.2)	0.6	(0.8)	7.1
Gross Profit	7,919	7,865	7,329	7,566	7,537	5,484	24.0	(0.7)	(6.8)	3.2	(0.4)	4.0
Operating Expenses	(5,685)	(5,610)	(4,979)	(5,231)	(5,232)	(3,940)	24.3	(1.3)	(11.2)	5.0	0.0	5.5
Operating Profit	2,234	2,254	2,350	2,335	2,305	1,544	23.3	0.9	4.2	(0.6)	(1.3)	0.2
Non Operating Income/(Loss)	78	151	77	105	73	69	11.8	92.6	(49.2)	36.8	(30.2)	25.6
Pretax Income	2,312	2,405	2,427	2,440	2,378	1,613	22.8	4.0	0.9	0.6	(2.5)	1.1
Tax Expenses	(426)	(471)	(537)	(502)	(483)	(311)	26.8	10.6	14.0	(6.5)	(3.7)	(3.9)
Minority interest	(590)	(583)	(595)	(630)	(623)	(441)	19.2	(1.3)	2.1	5.9	(1.1)	4.9
Net Income to Parent	1,297	1,352	1,295	1,309	1,272	860	23.3	4.3	(4.2)	1.1	(2.8)	1.1
Basic EPS (NT\$)	9.82	10.03	9.57	9.63	9.34	5.84	21.7	2.1	(4.6)	0.6	(3.0)	(6.6)
Key Financial Ratios (%)												
Gross Margin	86.2	83.8	79.8	81.9	82.2	79.7						
Operating Expense Ratio	61.9	59.8	54.2	56.6	57.1	57.3						
Operating Margin	24.3	24.0	25.6	25.3	25.1	22.4						
Effect Tax Rate	18.4	19.6	22.1	20.6	20.3	19.3						
Net Margin	14.1	14.4	14.1	14.2	13.9	12.5						



Five-Year Balance Sheet

(NIT\$ m)	2016	2017	2018	2019	2020	9M21	YoY (%)					
(NT\$ m)	2010	2017	2010	2017	2020	710121	2016	2017	2018	2019	2020	9M21
Total Assets	9,550	9,892	10,648	11,359	13,104	12,931	10.9	3.6	7.6	6.7	15.4	7.8
Cash	1,899	1,920	2,050	2,146	2,927	2,441	32.6	1.1	6.8	4.7	36.4	46.1
AR & NR	204	160	171	202	202	305	111.6	(21.5)	6.8	18.0	(0.2)	24.9
Inventories	435	492	563	546	689	783	21.0	13.1	14.4	(2.9)	26.2	8.7
Fixed Assets	6,084	6,355	5,927	6,454	7,308	7,199	8.7	4.5	(6.7)	8.9	13.2	(2.0)
Total Liabilities	3,767	3,564	3,715	3,888	5,126	3,158	(14.3)	(5.4)	4.2	4.7	31.8	(32.2)
AP & NP	198	323	262	223	255	318	29.6	63.2	(18.9)	(15.1)	14.7	32.9
Total Borrowing	1,206	1,022	1,119	1,177	1,921	209	(50.6)	(15.2)	9.5	5.2	63.3	(89.7)
Total Equity	5,783	6,328	6,933	7,471	7,978	9,773	37.1	9.4	9.6	7.8	6.8	33.3
Key Financial Ratios (%)												
A/R Turnover Days	5.9	7.0	6.5	7.3	7.9	10.8						
Inventory Turnover Days	113.0	109.5	102.4	119.3	136.4	145.3						
A/P Turnover Days	49.9	61.6	56.8	52.2	52.7	53.8						
Cash Conversion Days	69.0	54.9	52.1	74.4	91.6	102.3						
ROE (%)	31.3	27.0	23.7	22.0	19.9	17.4						
ROA (%)	14.3	13.9	12.6	11.9	10.4	10.3						
Net debt (cash)/Equity %	(12.0)	(14.2)	(13.4)	(13.0)	(12.6)	(22.8)						



Dividend Payout and Capex

(NT\$ m)	2015	2016	2017	2018	2019	2020
Net profit	1,052	1,297	1,352	1,295	1,309	1,272
Cash dividend	730	862	903	883	884	948
DPS (NT\$)	5.6	6.4	6.7	6.5	6.5	6.4
Payout ratio	69.4%	65.2%	66.6%	67.9%	67.4%	68.5%
Cash yield	2.6%	3.2%	2.9%	3.0%	3.3%	3.8%
Capex	2,635	736	772	1,116	630	1,214

Notes:

- 1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.
- 2. The capex for 2020 is mainly used for land acquisition for our Zhongli plant relocation and for new production facilities.
- 3. 2020 cash yield is calculated based on Grape King's 2021/6/2 closing share.





Appendix: Industry Trends



Taiwan health food industry

Taiwan's health food industry is growing

Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.

(NT\$ bn) Taiwan health food industry (NT\$ bn) 180 160 **CAGR 7.6%** 140 (2003-2019)120 100 80 60 40 20 2003 2008 2009 2010 2012 2013 2014 2017

Source: AC Nielsen

We keep gaining market share in Taiwan

We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.

Grape King's market share in Taiwan health food industry

	<u>2013</u>		<u>2019</u>
Taiwan health food	4.90%	-	5.60%
Mushroom	32.06%	→	44.93%
Probiotics	13.89%	→	30.64%
Energy drink	12.23%	→	11.22%


Source: AC Nielsen, Company data

"

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- 1) Reasonable product price (mark-up on pricing);
- Reasonable compensation structure (distribution of profit)

Member's system



According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration

Pro-Partner has highest sales per product among top 3 players



	Rank & Market	Member	Sales contribution				
	shares (%)	s ('000)	Per member (NT\$)	Per product (NT\$m)			
Pro-Partner	2 (9.8%)	200	43,300	288.7			
Nu Skin	3 (5.5%)	120	40,000	21.9			
Amway	1 (13.4%)	350	33,857	41.0			

2018

"


China health food industry

China's health food industry grew 21% CAGR between 2011-2018

China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 7 years.

China direct selling has significant growth from 2011-2018

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 47% in 2018.




Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.



China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



^{*}Notes: Global probiotics market includes probiotics supplement, probiotic yoghurt, and sour milk products.

Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.

Rank	Company	Brand	
1	P&G	Align	align
2	SANOFI	Enterogermina	Enterogermina
3	父 大正製業	Shin Biofermin S	Salar Production Salar S
7	新萄王生技 GRAFE KING BO	Probiotics & Prebiotics Super 13 Probiotics & Prebioti	CS HAIN

Source: Euromonitor

China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020

China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.

Taiwan and China probiotic supplement market are expected

According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.

China Probiotics Market (2014-2020) (Rmb bn) 100 85 80 60 40 20 2014 2015 2016 2017 2018(E) 2019(E) 2020(E)

yoghurt, and sour milk products.

Source: ASKCI

*Notes: China probiotics market includes probiotics supplement, probiotic

Probiotics Supplements Retail Value (2016-2021) (USD m) ■ Retail value 2016 • % expected growth 2016/2021 57% 2500 60% 46% 50% 2000 40% 1500 27% 25% 24% 30% 1000 20% 13% 500 10% 0%

Source: Euromonitor

